Extended Data Fig. 7: Minimal impact of subcutaneous ipilimumab on skin-infiltrating immune cells.
From: A neoantigen vaccine generates antitumour immunity in renal cell carcinoma
The proportion of each (a) myeloid cell and (b) lymphoid cell population after vaccination (week 4) was compared in patients who received the vaccine alone or vaccine plus subcutaneous ipilimumab (two-sided Wilcoxon test; n = 4 patients who received vaccine alone, and n = 5 patients who received vaccine + ipilimumab; boxplot hinges represent 25th to 75th percentiles, central lines represent the medians, the whiskers extend to lowest and highest values no greater than 1.5× interquartile range away from the 25th and 75th percentiles, and the dots indicate outliers).
